Literature DB >> 15050482

Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction.

Piera Angelica Merlini1, Massimo Cugno, Marco L Rossi, Pietro Agricola, Alessandra Repetto, Raffaella Fetiveau, Paolo Diotallevi, Umberto Canosi, Pier Mannuccio Mannucci, Diego Ardissino.   

Abstract

Thrombolytic therapy activates the contact system, and factor XII activation may activate the coagulation cascade and inflammation. It is not known whether an early inflammatory response is induced by thrombolytic therapy in patients with acute myocardial infarction (AMI). We prospectively measured the plasma levels of activated factor XII, cleaved kininogen, prothrombin fragment 1 + 2 (as indexes of the contact phase and coagulation activation), and interleukin-6 and C-reactive protein (CRP) (as indexes of inflammation) in 39 patients hospitalized for AMI within 12 hours of symptom onset: 26 receiving thrombolytic therapy and 13 heparin alone. Blood samples were collected at baseline and after 90 minutes and 24 hours. Patients undergoing thrombolysis had a significant early increase in activated factor XII (from 2.2 ng/ml at baseline to 4.7 ng/ml after 90 minutes; p = 0.0001), cleaved kininogen (from 26% to 37%; p = 0.001), and fragment 1 + 2 (from 1.4 to 2.1 nmol/L; p = 0.0001), whereas the 24-hour levels were similar to baseline levels. The levels of interleukin-6 significantly increased during the first 90 minutes (from 3.9 to 6.3 microg/ml; p = 0.001), and were even higher after 24 hours (11.9 ng/ml, p = 0.0001). CRP levels increased only after 24 hours (p = 0.0001). There were no changes in these parameters in patients receiving heparin alone, except for a 24-hour increase in interleukin-6 and CRP levels. Thus, in patients with AMI receiving thrombolytic therapy, early activation of inflammation parallels the activation of the contact system and the coagulation cascade, which might contribute to microvascular obstruction and reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050482     DOI: 10.1016/j.amjcard.2003.12.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  Off-Pump Coronary Artery Bypass Leads to a Regional Hypercoagulable State Not Detectable Using Systemic Markers.

Authors:  Zachary N Kon; Michael H Kwon; Michael J Collins; Seeta Kallam; Rupali Sangrampurkar; Toshinaga Ozeki; Emile N Brown; Linda G Romar; Richard N Pierson; James S Gammie; James M Brown; Bartley P Griffith; Robert S Poston
Journal:  Innovations (Phila)       Date:  2006

3.  Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome.

Authors:  Kyeong Ho Yun; Myung Ho Jeong; Seok Kyu Oh; Sang Jae Rhee; Eun Mi Park; Eun Mi Lee; Nam Jin Yoo; Nam-Ho Kim; Young Keun Ahn; Jin-Won Jeong
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

4.  Effect of Aspiration Thrombectomy on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction With an Elevated Neutrophil Count.

Authors:  Hye Young Lee; Jeong Hoon Kim; Byung Ok Kim; Yoon Jung Kang; Hyo Seung Ahn; Mee Won Hwang; Kyoung Min Park; Young Sup Byun; Choong Won Goh; Kun Joo Rhee
Journal:  Korean Circ J       Date:  2011-02-28       Impact factor: 3.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.